James Andrea S. 4
4 · Oncocyte Corp · Filed Oct 15, 2024
Insider Transaction Report
Form 4
James Andrea S.
Chief Financial Officer
Transactions
- Award
Options to Purchase Common Stock
2024-10-11+200,000→ 200,000 totalExercise: $2.87Exp: 2034-06-20→ Common Stock (200,000 underlying) - Award
Restricted Stock Units
2024-10-11+100,000→ 100,000 total→ Common Stock (100,000 underlying)
Footnotes (3)
- [F1]As previously disclosed in the Form 4 filed by the Reporting Person on June 24, 2024 (the "Prior Form 4"), the derivative securities were granted on June 20, 2024 (the "Grant Date"), but such award was subject to stockholder approval of an increase in the number of shares available for issuance under the Oncocyte Corporation Amended and Restated 2018 Equity Incentive Plan. Such stockholder approval was obtained on October 11, 2024.
- [F2]The Option shall vest as follows, subject to the Reporting Person's continued compliance with any restrictive covenants by which the Reporting Person may be bound and continuous service as an employee of the Issuer or a subsidiary of the Issuer from June 17, 2024, through the applicable vesting date: (A) twenty-five percent (25%) of the shares subject to the Option will vest and thereby become exercisable upon the one-year anniversary of the Grant Date, and (B) 75% of the shares subject to the Option will vest in thirty-six (36) substantially equal monthly installments thereafter.
- [F3]See Exhibit 99 attached to the Prior Form 4 which is incorporated by reference herein.